Magic mushroom compound matches antidepressant in clinical trialThe active compound in magic mushrooms – psilocybin – seems to be at least as effective as a Share XMagic mushroom compound matches antidepressant in clinical trialhttps://pharmaphorum.com/news/magic-mushroom-compound-matches-antidepressant-in-clinical-trial/
Tribunal maintains Lexon’s £1.2m fine for breaking competition lawPharmaceutical wholesaler Lexon (UK) has lost its appeal against a £1.2 million fine in a case that accused Share XTribunal maintains Lexon’s £1.2m fine for breaking competition lawhttps://pharmaphorum.com/news/tribunal-maintains-lexons-1-2m-fine-for-breaking-competition-law/
Otsuka, Click trial digital depression therapy with GoogleOtsuka and Click Therapeutics are working with Verily, the healthcare subsidiary of Google owners Alphabet, on a fully Share XOtsuka, Click trial digital depression therapy with Googlehttps://pharmaphorum.com/news/otsuka-click-trial-digital-depression-therapy-with-google/
Novartis buys neurology biotech Cadent for up to $770mNovartis is to buy neuroscience drugs firm Cadent Therapeutics in a deal worth up to $770 million. The Share XNovartis buys neurology biotech Cadent for up to $770mhttps://pharmaphorum.com/news/novartis-buys-neurology-biotech-cadent-for-up-to-770m/
VC fund dedicated to psychedelic meds launches in UKIn the last few years, biopharma companies focusing on psychedelic medicines have been springing up like mushrooms – Share XVC fund dedicated to psychedelic meds launches in UKhttps://pharmaphorum.com/news/vc-fund-dedicated-to-psychedelic-meds-launches-in-uk/
Biogen bulks up pipeline with Sage drugs in $3bn dealWith the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore Share XBiogen bulks up pipeline with Sage drugs in $3bn dealhttps://pharmaphorum.com/news/biogen-bulks-up-pipeline-with-sage-drugs-in-3bn-deal/
MindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOCompass Pathways and its potential magic mushroom depression drug went public last week – and now psychedelic therapy Share XMindMed aims for Nasdaq listing after Compass’ magic mushroom-fuelled IPOhttps://pharmaphorum.com/news/mindmed-aims-for-nasdaq-listing-after-compass-magic-mushroom-fuelled-ipo/
Compass plans $100m IPO to fund magic mushroom depression drugUK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its Share XCompass plans $100m IPO to fund magic mushroom depression drughttps://pharmaphorum.com/news/compass-plans-100m-ipo-to-fund-magic-mushroom-depression-drug/
NICE rejects Janssen’s depression spray Spravato for second timeNICE has rejected regular NHS funding for Janssen’s depression spray Spravato (esketamine) for a second time, although the Share XNICE rejects Janssen’s depression spray Spravato for second timehttps://pharmaphorum.com/news/nice-rejects/
